https://www.selleckchem.com/
Conclusion The extreme clinical heterogeneity and the chronic progression of Atopic Dermatitis need for newer, safer and more effective treatments, able to control the disease and to improve the quality of life of affected patients. Dupilumab, and the other monoclonal antibodies and small molecules currently under investigation aim to improve the clinical management of Atopic Dermatitis.Background Bacteriocins (Bac1, Bac2, and Bac3) from Weissella confusa MBF8-1, weissellicin-MBF, have been reported as potential alternative substances as well as complements
Like
Comment
Share
